IL-GLOBAL-DAIRY
A first-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope.
“The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform.
A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate Change Conference, COP26, in November.
New research to guide the initiative
Research is underway to identify where positive climate change action is possible across all dairy production systems and regions throughout the world. The study is being conducted by the Global Research Alliance on Agricultural Greenhouse Gases (GRA), the UN Food and Agriculture Organisation, Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre. Preliminary findings include:
- Positive change is possible across all dairy systems and regions. Although there is a wide variety of production systems globally, there are opportunities for all to reduce greenhouse gas emission (GHG) intensity.1
- Collaboration is needed to reduce dairy’s emissions. Many climate, poverty, and malnutrition challenges can be addressed through adoption of best practices in similar dairy systems.2
- Reducing methane may be key to fast results. Methane, a primary GHG produced by ruminant livestock, is short-lived. As a result, more reductions in methane would have a more immediate effect on warming.3
- Dairy already has the means to reduce a significant proportion of emissions. 4 Initial evidence suggests emissions can be reduced up to 40 percent in some systems by improving productivity and resource use efficiency.
- Defining terminologies and targets will focus efforts to achieve the best results. As indicated in the Intergovernmental Panel on Climate Change (IPCC) Special Report: Global Warming of 1.5°C, dairy’s carbon dioxide emissions need to strive to Net Zero, but its methane reduction can range from 24-47 percent, and its nitrous oxide reduction can be 26 percent.5
“Our initial analysis suggests that wider use of existing GHG mitigation technologies will make an important impact in reducing dairy’s emissions in the short term, while the development of new innovations takes place,” said Hayden Montgomery, Special Representative of GRA. “This initiative may ultimately act as a blueprint for other livestock sectors,” he added.
For more information about Pathways to Dairy Net Zero , visit: www.GlobalDairyPlatform.com/PathwaysToDairyNetZero .
You can register here for the UN Food Systems Pre-Summit affiliated session “Raising the climate ambition for the agriculture sector: An approach from dairy” on Monday, July 26, at 19:30 CEST.
References:
- Food and Agriculture Organization of the United Nations (FAO). 2010. Greenhouse Gas Emissions from the Dairy Sector: A Life Cycle Assessment. Available at: http://www.fao.org/3/k7930e/k7930e00.pdf [Accessed July 2021].
- Food and Agriculture Organization of the United Nations (FAO). 2019. Climate change and the global dairy cattle sector: The role of the dairy sector in a low‐carbon future. Available at: http://www.fao.org/3/CA2929EN/ca2929en.pdf [Accessed July 2021].
- UN Environment Programme. 2021. Global Methane Assessment: Benefits and Costs of Mitigating Methane Emissions. Available at: https://www.unep.org/resources/report/global-methane-assessment-benefits-and-costs-mitigating-methane-emissions [Accessed July 2021].
- Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
- The Intergovernmental Panel on Climate Change (IPCC). 2018. Global warming of 1.5°C. An IPCC Special Report on the impacts of global warming of 1.5°C above pre-industrial levels and related global greenhouse gas emission pathways, in the context of strengthening the global response to the threat of climate change, sustainable development, and efforts to eradicate poverty. Available at: https://www.ipcc.ch/site/assets/uploads/sites/2/2019/06/SR15_Full_Report_Low_Res.pdf [Accessed July 2021].
About Pathways to Dairy Net Zero
This is a vibrant, growing movement, the first of its kind in the world. It brings together dairy production systems of every size and type, as well as organizations throughout the dairy supply chain. Collaborators include Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network. The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.
www.GlobalDairyPlatform.com/PathwaysToDairyNetZero
View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005299/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
